Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Orvosi Hetilap|December 24, 2008
[Neoadjuvant systemic therapy in breast cancer]Zsuzsanna Kahán, Aliz Nikolényi, Gabriella Uhercsák, et al.
Oncology|June 5, 2010
Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancerGyöngyi Kelemen, Gabriella Uhercsák, Katalin Ormándi, et al.
Magyar Onkologia|September 27, 2014
[Therapeutic significance of sunitinib-induced "off-target" side effects]Anikó Maráz, Adrienn Cserháti, Gabriella Uhercsák, et al.
Magyar Sebeszet|September 4, 2012
[Experimental studies on microcirculatory inflammatory reactions of the urinary bladder]Péter Járomi, Andrea Szabó, Dénes Garab, et al.
Hepato-Gastroenterology|September 23, 2011
Efficacy and drawbacks of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the thoracic esophagusAntal Wolfárd, Attila Paszt, Károly Szentpáli, et al.
BMC Cancer|March 17, 2018
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinomaAnikó Maráz, Adrienn Cserháti, Gabriella Uhercsák, et al.
Anticancer Research|August 9, 2015
Cardiac Surveillance Findings During Adjuvant and Palliative Trastuzumab Therapy in Patients with Breast CancerErzsébet Valicsek, Renáta Kószó, Ágnes Dobi, et al.
Oncotargets and Therapy|September 21, 2018
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case seriesOrsolya Rusz, Renáta Kószó, Ágnes Dobi, et al.
Pathology Oncology Research : POR|March 11, 2015
One-Year Neoadjuvant Endocrine Therapy in Breast CancerOrsolya Rusz, András Vörös, Zoltán Varga, et al.
Pathology Oncology Research : POR|June 18, 2011
Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapyAlíz Nikolényi, Gabriella Uhercsák, Melinda Csenki, et al.
Pageof 2